Rebecca L Sedjo1, Shirley W Flatt2, Tim Byers3, Graham A Colditz4, Wendy Demark-Wahnefried5, Patricia A Ganz6, Kathleen Y Wolin7, Anthony Elias3, Helen Krontiras5, Jingxia Liu4, Michael Naughton4, Bilgé Pakiz2, Barbara A Parker2, Holly Wyatt3, Cheryl L Rock2. 1. University of Colorado Anschutz Medical Campus, 13001 East 17th Place, MS F519, Aurora, CO, 80045, USA. rebecca.sedjo@ucdenver.edu. 2. University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA. 3. University of Colorado Anschutz Medical Campus, 13001 East 17th Place, MS F519, Aurora, CO, 80045, USA. 4. Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8100, Saint Louis, MO, 63110, USA. 5. University of Alabama at Birmingham, 1824 6th Avenue, Wallace Tumor Institute, Rm. 310D, Birmingham, AL, 35294, USA. 6. Jonsson Comprehensive Cancer Center, and the UCLA Fielding School of Public Health, University of California Los Angeles, 650 Charles Young Drive South, Room A2-125 CHS, Los Angeles, 90095, CA, USA. 7. Coeus Health LLC, 222 Merchandise Mart Pl, Suite 1230, Chicago, IL, 60654, USA.
Abstract
PURPOSE: Comorbid medical conditions are common among breast cancer survivors, contribute to poorer long-term survival and increased overall mortality, and may be ameliorated by weight loss. This secondary analysis evaluated the impact of a weight loss intervention on comorbid medical conditions immediately following an intervention (12 months) and 1-year postintervention (24 months) using data from the Exercise and Nutrition to Enhance Recovery and Good health for You (ENERGY) trial-a phase III trial which was aimed at and successfully promoted weight loss. METHODS: ENERGY randomized 692 overweight/obese women who had completed treatment for early stage breast cancer to either a 1-year group-based behavioral intervention designed to achieve and maintain weight loss or to a less intensive control intervention. Minimal support was provided postintervention. New medical conditions, medical conditions in which non-cancer medications were prescribed, hospitalizations, and emergency room visits, were compared at baseline, year 1, and year 2. Changes over time were analyzed using chi-squared tests, Kaplan-Meier, and logistic regression analyses. RESULTS: At 12 months, women randomized to the intervention had fewer new medical conditions compared to the control group (19.6 vs. 32.2 %, p < 0.001); however, by 24 months, there was no longer a significant difference. No difference was observed in each of the four conditions for which non-cancer medications were prescribed, hospital visits, or emergency visits at either 12 or 24 months. CONCLUSIONS: These results support a short-term benefit of modest weight loss on the likelihood of comorbid conditions; however, recidivism and weight regain likely explain no benefit at 1-year postintervention follow-up.
RCT Entities:
PURPOSE: Comorbid medical conditions are common among breast cancer survivors, contribute to poorer long-term survival and increased overall mortality, and may be ameliorated by weight loss. This secondary analysis evaluated the impact of a weight loss intervention on comorbid medical conditions immediately following an intervention (12 months) and 1-year postintervention (24 months) using data from the Exercise and Nutrition to Enhance Recovery and Good health for You (ENERGY) trial-a phase III trial which was aimed at and successfully promoted weight loss. METHODS: ENERGY randomized 692 overweight/obesewomen who had completed treatment for early stage breast cancer to either a 1-year group-based behavioral intervention designed to achieve and maintain weight loss or to a less intensive control intervention. Minimal support was provided postintervention. New medical conditions, medical conditions in which non-cancer medications were prescribed, hospitalizations, and emergency room visits, were compared at baseline, year 1, and year 2. Changes over time were analyzed using chi-squared tests, Kaplan-Meier, and logistic regression analyses. RESULTS: At 12 months, women randomized to the intervention had fewer new medical conditions compared to the control group (19.6 vs. 32.2 %, p < 0.001); however, by 24 months, there was no longer a significant difference. No difference was observed in each of the four conditions for which non-cancer medications were prescribed, hospital visits, or emergency visits at either 12 or 24 months. CONCLUSIONS: These results support a short-term benefit of modest weight loss on the likelihood of comorbid conditions; however, recidivism and weight regain likely explain no benefit at 1-year postintervention follow-up.
Entities:
Keywords:
Breast cancer survivorship; Comorbid conditions; Weight loss
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Bette J Caan; Jennifer A Emond; H Irene Su; Ruth E Patterson; Shirley W Flatt; Ellen B Gold; Vicky A Newman; Cheryl L Rock; Cynthia A Thomson; John P Pierce Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: Ikuyo Imayama; Catherine M Alfano; Marian L Neuhouser; Stephanie M George; Ashley Wilder Smith; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Ching-Yun Wang; Catherine Duggan; Rachel Ballard-Barbash; Anne McTiernan Journal: Breast Cancer Res Treat Date: 2013-07 Impact factor: 4.872
Authors: Anna H Wu; Allison W Kurian; Marilyn L Kwan; Esther M John; Yani Lu; Theresa H M Keegan; Scarlett Lin Gomez; Iona Cheng; Salma Shariff-Marco; Bette J Caan; Valerie S Lee; Jane Sullivan-Halley; Chiu-Chen Tseng; Leslie Bernstein; Richard Sposto; Cheryl Vigen Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-25 Impact factor: 4.254
Authors: Ruth E Patterson; Shirley W Flatt; Nazmus Saquib; Cheryl L Rock; Bette J Caan; Barbara A Parker; Gail A Laughlin; Kirsten Erickson; Cynthia A Thomson; Wayne A Bardwell; Richard A Hajek; John P Pierce Journal: Breast Cancer Res Treat Date: 2010-01-14 Impact factor: 4.872
Authors: Sarah Nechuta; Wei Lu; Ying Zheng; Hui Cai; Ping-Ping Bao; Kai Gu; Wei Zheng; Xiao Ou Shu Journal: Breast Cancer Res Treat Date: 2013-04-19 Impact factor: 4.872
Authors: Dejana Braithwaite; Dan H Moore; William A Satariano; Marilyn L Kwan; Robert A Hiatt; Candyce Kroenke; Bette J Caan Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-05-09 Impact factor: 4.254
Authors: Kate Ormiston; Monica M Gaudier-Diaz; Tial TinKai; Julie Fitzgerald; Rachel M Cole; Rebecca Andridge; Maryam Lustberg; A Courtney DeVries; Tonya Orchard Journal: Nutr Neurosci Date: 2021-11-12 Impact factor: 4.062
Authors: Thomas Semlitsch; Cornelia Krenn; Klaus Jeitler; Andrea Berghold; Karl Horvath; Andrea Siebenhofer Journal: Cochrane Database Syst Rev Date: 2021-02-08
Authors: Nathalie LeVasseur; Wei Cheng; Sasha Mazzarello; Mark Clemons; Lisa Vandermeer; Lee Jones; Anil Abraham Joy; Pauline Barbeau; Dianna Wolfe; Nadera Ahmadzai; Mona Hersi; Carol Stober; Risa Shorr; John Hilton; Brian Hutton Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240
Authors: Antonio Di Meglio; Julie Havas; Arnauld S Gbenou; Elise Martin; Mayssam El-Mouhebb; Barbara Pistilli; Gwenn Menvielle; Agnes Dumas; Sibille Everhard; Anne-Laure Martin; Paul H Cottu; Florence Lerebours; Charles Coutant; Anne Lesur; Olivier Tredan; Patrick Soulie; Laurence Vanlemmens; Florence Joly; Suzette Delaloge; Patricia A Ganz; Fabrice André; Ann H Partridge; Lee W Jones; Stefan Michiels; Ines Vaz-Luis Journal: J Clin Oncol Date: 2022-04-21 Impact factor: 50.717